AGIO Stock Risk & Deep Value Analysis
Agios Pharmaceuticals Inc
DVR Score
out of 10
What You Need to Know About AGIO Stock
We analyzed Agios Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AGIO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
AGIO Risk Analysis & Red Flags
What Could Go Wrong
Agios is quickly burning through cash and remains unprofitable, with negative free cash flow projected through 2028. If commercial traction for PYRUKYND decelerates significantly or the mitapivat accelerated approval pathway for sickle cell disease faces unexpected hurdles, the company may need to raise additional capital through dilutive equity offerings sooner than anticipated, pressuring the stock price.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Significant ongoing cash burn, with profitability not expected until after 2028.
- ⚠
Direct and strong competitive threat from Novo Nordisk's etavopivat, which showed superior VOC reduction data in sickle cell disease.
- ⚠
Mitapivat missed primary efficacy endpoint for VOCs in Phase III RISE UP trial, relying on accelerated approval via hemoglobin response for SCD.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or weak forward guidance
- 📅
Negative updates from FDA regarding sNDA pathway for mitapivat in SCD
- 📅
Further positive competitive data from Novo Nordisk (etavopivat)
When to Reconsider
- 🚪
Exit if PYRUKYND quarterly revenue growth drops below 20% YoY for two consecutive quarters.
- 🚪
Sell if company announces a highly dilutive capital raise (e.g., >15% share increase) without a clear, immediate catalyst.
- 🚪
Exit if a major competitor receives broader or more favorable regulatory approval in target indications (e.g., Novo Nordisk for SCD with superior label).
Unlock AGIO Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Agios Pharmaceuticals is a high-risk, high-reward investment proposition built on the commercial success of its FDA-approved drug PYRUKYND and the potential expansion into broader rare blood disorders, including an accelerated approval pathway for sickle cell disease. Despite significant cash burn and increasing competitive pressure from Novo Nordisk, the company's strong revenue growth for its lead product and removal of previous fraud allegations provide a clearer, albeit still challenging, path to unlocking significant upside potential within 3-5 years as its therapies gain market share.
Is AGIO Stock Undervalued?
Unlock the full AI analysis for AGIO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
AGIO Price Targets & Strategy
12-Month Target
$44.00
Bull Case
$60.00
Bear Case
$25.00
Valuation Basis
Based on analyst median price target of $44, implying ~63% upside from current price, reflecting commercial traction of PYRUKYND and pipeline potential.
Entry Strategy
Consider dollar-cost averaging on dips to recent support levels, potentially in the $25-$27 range, especially prior to Q1 earnings if no negative news emerges.
Exit Strategy
Take profit at analyst median target of $44, with further tranches at $50-$60. Set a stop loss below $22, which would indicate a break of key support.
Portfolio Allocation
5% for aggressive risk tolerance, reflecting high growth potential balanced by significant competitive and clinical risks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is AGIO Financially Healthy?
Valuation
P/E Ratio
6.96
Forward P/E
6.96
EV/EBITDA
6.96
PEG Ratio
6.96
Price/Book
1.98
Price/Sales
56.19
Profitability
Gross Margin
88.26%
Operating Margin
-873.87%
Net Margin
-764.01%
Return on Equity
-31.07%
Revenue Growth
48.03%
EPS
$-7.12
Balance Sheet
Current Ratio
11.46
Quick Ratio
10.52
Debt/Equity
0.03
Total Debt
$6.96
Cash & Equivalents
$6.96
Cash Flow
Operating Cash Flow
$6.96
Free Cash Flow
-$470.31M
EBITDA
-$470.31M
Other
Beta (Volatility)
0.61
Does AGIO Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable, but facing erosion risk in specific indications (e.g., sickle cell disease) due to competitive innovation.
Moat Sources
3 Identified
The moat primarily relies on the intellectual property surrounding mitapivat and its derivatives. Its durability will depend on the strength of its patent portfolio and the ability to differentiate its clinical profile against emerging competitors, especially in larger markets like sickle cell disease.
Moat Erosion Risks
- •Newer, more effective competitor drugs eroding market share in target indications (e.g., Novo Nordisk's etavopivat for SCD).
- •Patent expiry or successful challenges to existing patents.
- •Inability to expand into larger indications, limiting the utility of the core IP.
AGIO Competitive Moat Analysis
Sign up to see competitive advantages
AGIO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with recent negative sentiment due to Novo Nordisk's competitive news, but underlying positive buzz around PYRUKYND's commercial growth.
Institutional Sentiment
Positive, with a 'Strong Buy' consensus among analysts and multiple price targets implying significant upside, despite recent target downgrades by H.C. Wainwright due to competitive data.
Insider Activity (Form 4)
CEO Brian Goff sold 19,068 shares ($661,850), CFO Cecilia Jones sold 3,141 shares ($109,000), and CLO James William Burns sold 3,280 shares ($113,849) on April 2, 2026. These were tax withholding sales following the vesting of performance share units tied to a regulatory milestone (FDA accelerated approval pathway for mitapivat).
Options Flow
Normal options activity; no specific unusual activity identified in the provided research.
Earnings Intelligence
Next Earnings
2026-04-29
Surprise Probability
Medium
Historical Earnings Pattern
Company appears to be in a growth phase where positive updates on drug commercialization and pipeline progress can lead to rallies, but competitive or clinical setbacks cause significant pullbacks (e.g., 23-25% drop on Novo Nordisk data).
Key Metrics to Watch
Competitive Position
Top Competitor
NVO
Market Share Trend
Gaining market share with PYRUKYND in its approved indications (e.g., PK deficiency), but faces significant competition in expanding into sickle cell disease with Novo Nordisk taking an early lead on efficacy data.
Valuation vs Peers
Valuation metrics are not provided in the research for direct peer comparison, but analysts suggest AGIO is undervalued relative to its potential. However, it trades at a discount in market capitalization to more established large-cap biopharma peers.
Competitive Advantages
- •Proprietary Pyruvate Kinase activator technology (mitapivat)
- •FDA-approved drug (PYRUKYND) with strong commercial growth
- •Established regulatory pathways for rare blood disorders
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive AGIO Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (April 29, 2026)
- •Pre-supplemental NDA meeting for mitapivat in SCD (Q1 2026)
- •Submission of marketing application for mitapivat in SCD (following FDA meeting)
Medium-Term (6-18 months)
- •Continued commercial growth and expansion of PYRUKYND (mitapivat) into new regions or indications (e.g., thalassemia)
- •Further clinical trial data readouts for mitapivat in various indications
- •Strategic partnerships to accelerate market penetration
Long-Term (18+ months)
- •Establishment of mitapivat as a leading therapy in PK deficiency, thalassemia, and/or sickle cell disease
- •Expansion of pipeline beyond current lead assets
- •Potential acquisition target if pipeline matures significantly
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for AGIO?
- ✓
Acceleration in PYRUKYND revenue growth beyond current rates.
- ✓
Positive clinical data readouts from ongoing trials for mitapivat in new indications.
- ✓
Achieving positive free cash flow earlier than forecasted 2029.
Bull Case Analysis
See what could go right with Premium
Competing with AGIO
See how Agios Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals Inc AGIO | $1.6B | 6.9 | 7.0 | $44.8M | -764.0% | 48.0% | |
Novo Nordisk A/S NVO | $1.1T | 1.4 | 10.7 | — | 33.1% | 6.4% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Agios Pharmaceuticals Inc Makes Money
Agios Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare and severe diseases. It primarily makes money by researching, developing, manufacturing, and selling prescription drugs. Its current flagship product, PYRUKYND (mitapivat), is an oral activator of pyruvate kinase (PK) designed to treat various rare blood disorders, with its initial approval for pyruvate kinase deficiency and recent FDA approval for an unspecified indication in December 2025. The company generates revenue from direct product sales and potential licensing agreements for its pipeline candidates.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Agios Pharmaceuticals Inc (AGIO)?
As of April 22, 2026, Agios Pharmaceuticals Inc has a DVR Score of 6.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Agios Pharmaceuticals Inc?
Agios Pharmaceuticals Inc's market capitalization is approximately $1.6B..
What is the risk level for AGIO stock?
Our analysis rates Agios Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of AGIO?
Agios Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 7.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Agios Pharmaceuticals Inc's revenue growing?
Agios Pharmaceuticals Inc has reported revenue growth of 48.0%. The company is showing strong top-line momentum.
Is AGIO stock profitable?
Agios Pharmaceuticals Inc has a profit margin of -764.0%. The company is currently unprofitable.
How often is the AGIO DVR analysis updated?
Our AI-powered analysis of Agios Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 22, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AGIO (Agios Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.